Transcriptional regulation of DC fate specification by Bosteels, Cedric & Scott, Charlotte
Contents lists available at ScienceDirect
Molecular Immunology
journal homepage: www.elsevier.com/locate/molimm
Transcriptional regulation of DC fate specification
Cédric Bosteelsa,b, Charlotte L. Scotta,c,*
a VIB-UGent Center for Inflammation Research, Technologiepark-Zwijnaarde 71, Ghent, 9052, Belgium
bDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent 9000, Belgium
c Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
A R T I C L E I N F O
Keywords:
Dendritic cells
Transcription Factors
DC fate
Irf4
Irf8
Zeb1
Zeb2
Notch
Tbet
Klf4
A B S T R A C T
Dendritic cells function in the immune system to instruct adaptive immune cells to respond accordingly to
different threats. While conventional dendritic cells can be subdivided into two main subtypes, termed cDC1s
and cDC2s, it is clear that further heterogeneity exists within these subtypes, particularly for cDC2s.
Understanding the signals involved in specifying each of these lineages and subtypes thereof is crucial to (i)
enable us to determine their specific functions and (ii) put us in a position to be able to target these cells to
promote or prevent a specific function in any given disease setting. Although we still have much to learn re-
garding the specification of these cells, here we review the most recent advances in our understanding of this and
highlight some of the next questions for the future.
1. Introduction
Dendritic cells (DCs) are professional antigen-presenting cells with
nonredundant functions in both innate and adaptive immunity. While
patrolling peripheral tissues, DCs sample antigens and integrate en-
vironmental cues regarding the nature of the threats they encounter to
initiate appropriate immune responses. Dendritic cells develop in the
bone marrow (BM) through different progenitor stages in a tightly
regulated transcriptional process (Sichien et al., 2017) and reviewed
elsewhere in this issue) giving rise to plasmacytoid DCs (pDCs) and pre-
conventional DCs (pre-cDCs). However, the DC nature of pDCs is cur-
rently challenged as they have also been shown to differentiate from
lymphoid cell progenitors (Dekker et al., 2018; Dress et al., 2019;
Rodrigues et al., 2018). As these cells are discussed in detail in other
reviews in this issue, we will focus this review on conventional DCs
(cDCs). Upon their egress from the BM, pre-cDCs seed lymphoid and
most non-lymphoid tissue where they further differentiate into cDCs
driven by environmental cues and the concerted actions of transcription
factors (TFs) (Sichien et al., 2017). Both the development, homeostasis
and function of cDCs requires Fms-related tyrosine kinase 3 (Flt3) re-
ceptor signaling (Fujita et al., 2019; Ginhoux et al., 2009; Onai et al.,
2006; Waskow et al., 2008). Based on differences in transcriptional
control, specialized function, phenotype and ontogeny, mature cDCs
are further subdivided into cDC1s and cDC2s (Guilliams et al., 2014).
Transcriptionally, cells of the cDC1 and cDC2 lineages are com-
monly distinguished based on their mutually exclusive expression of
interferon-regulatory factor 8 (IRF8) and IRF4 respectively (Guilliams
et al., 2016; Murphy et al., 2016). Functionally, cDC1s excel in antigen
cross-presentation to CD8 T cells, whereas cDC2s typically drive CD4 T
cells toward distinct effector subsets. While the cDC1 subset is precisely
delineated by the expression of specific markers (such as XCR1) and
relies on a distinct set of TFs, cDC2s seem more heterogenous on a
transcriptional level and express surface markers (such as SIRPα and
CD11b) that often overlap with macrophages and monocyte-derived
cells (MCs) (Guilliams et al., 2016).
Already in the BM pre-cDCs become gradually committed to the
cDC1 or cDC2 fate and enter the bloodstream as pre-cDC1s and pre-
cDC2s respectively (Breton et al., 2016; Grajales-Reyes et al., 2015; Ma
et al., 2019; Schlitzer et al., 2015; See et al., 2017; Villani et al., 2017).
Guided by tissue-specific signals, such as those derived from the local
niche or invading pathogens, pre-cDCs and cDCs alter their transcrip-
tional profile that dictates a functional module best suited to deal with
the requirements of the current microenvironment (Roquilly et al.,
2017). This can result in a change of surface markers and/or de-
pendency on certain TFs to exert these functions, and as such cDCs may
obtain a maturation state different from the classically defined subset.
In this review we will focus on recent findings regarding the factors that
regulate this fate decision and the functional adaptations of the
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different cDC subsets.
2. Irf8 and Batf3
Irf8, formerly known as interferon consensus binding protein
(ICSBP) plays an important lineage-determining role in the BM at sev-
eral developmental stages of monocytes, pDCs and cDC1s (Bagadia
et al., 2019; Durai et al., 2019; Grajales-Reyes et al., 2015; Kurotaki
et al., 2018; Murphy et al., 2016; Sichien et al., 2016). The action of
IRF8 at the macrophage and DC precursor (MDP) and common mono-
cyte/macrophage precursor (cMoP) stages is crucial for monocyte de-
velopment and the exclusion of granulocyte potential (Kurotaki et al.,
2014; Sichien et al., 2016). Beyond the cMoP stage, Irf8 is redundant for
the survival of monocytes or monocyte-derived cells (MCs) (Kurotaki
et al., 2013; Sichien et al., 2016), yet the functional role of IRF8 in these
cells remains largely unknown.
By conditionally deleting Irf8 at different stages of DC development,
Irf8 has been shown to be a terminal selector for cDC1s as it is required
for the specification of pre-cDCs toward terminally differentiated cDC1s
(Bajaña et al., 2016; Grajales-Reyes et al., 2015; Luda et al., 2016;
Sichien et al., 2016) and that its continuous high expression through
BATF3-mediated autoactivation is required to maintain the identity of
cDC1s (Grajales-Reyes et al., 2015). Two recent reports by the Murphy
lab, deleting specific enhancers within Irf8 and employing a genetic
epistasis strategy, (Bagadia et al., 2019; Durai et al., 2019) have offered
insights in the mechanism and functional hierarchy of TFs involved in
Irf8 expression and subsequent DC fate specification. The Irf8 gene
carries three distinct enhancers bound by specific TFs that regulate Irf8
at different stages during development (Durai et al., 2019). Binding of
the TF PU.1 to the−50 kb (relative to the Irf8 transcriptional start site)
enhancer was shown to regulate Irf8 levels in mature monocytes and
some macrophages populations (Durai et al., 2019), but was not re-
quired for Irf8 expression in MDPs or for the downstream DC popula-
tions as previously reported (Schönheit et al., 2013). The +41 kb Irf8
enhancer likely activated by E2A (encoded by Tcf3) is required to
specify common DC precursors (CDPs) to pre-cDC1s by promoting IRF8
expression. In addition, the +41 kb Irf8 enhancer is also required for
normal pDC phenotype with Irf8 +41kb-/- pDCs having a similar phe-
notype to Irf8-/- pDCs (Durai et al., 2019; Sichien et al., 2016) poten-
tially through binding another E protein, E2-2 (encoded by Tcf4), the
lineage-determining TF of pDCs (Cisse et al., 2008). Once IRF8 ex-
pression is induced in cDC1-committed progenitors, the +32 kb Irf8
enhancer, which is activated by BATF3 and IRF8 itself (Grajales-Reyes
et al., 2015), becomes active in the pre-cDC1 stage, promoting both
their transition to mature cDC1s and their maintenance by sustaining
IRF8 expression. This essential switch from the E2A-dependent +41 kb
Irf8 enhancer in DC progenitors to the BATF3-dependent +32 kb en-
hancer in mature cDC1s depends on a NFIL3-ZEB2-ID2 regulatory cir-
cuit in which NFIL3 enforces ID2 expression by suppressing ZEB2 (see
below) (Bagadia et al., 2019). Ultimately, ID2 inhibits the E2A activity
at the +41 kb Irf8 enhancer from the pre-cDC1 stage onwards, thereby
mediating the switch to the BATF3-controlled +32 kb Irf8 enhancer in
mature cDC1s.
As the +32 kb enhancer is absolutely required for cDC1 develop-
ment, the +32 kb−/− mice generated as part of this study (Durai et al.,
2019) represent a nice tool to further study cDC1 function, without
compensatory mechanisms at play as previously observed for the loss of
Batf3, Nfil3 and Id2 (Seillet et al., 2013). Nevertheless, studies using
Batf3 or Irf8 KO mice have put forward the cDC1 branch as a major
cellular source of IL-12 in several models of infection with intracellular
pathogens (Everts et al., 2016; Hildner et al., 2008; Martínez-López
et al., 2015; Mashayekhi et al., 2011; Scharton-Kersten et al., 1997;
Schiavoni et al., 2002). This may result from the constitutive expression
of Irf8 in cDC1s (Aliberti et al., 2003; Everts et al., 2016; Sichien et al.,
2016), as Irf8 has previously been suggested to play a role in the ex-
pression of Il12-genes in macrophages, (Liu et al., 2004; Scharton-
Kersten et al., 1997; Wang et al., 2000). However, as it is not possible to
uncouple Irf8 expression and IL-12 production by cDC1s (cDC1s do not
develop in the absence of Irf8) this remains to tested. As cDC2s can also
express Il12b (Kinnebrew et al., 2012; Satpathy et al., 2013; un-
published data) and IFN-γ driven IL-12 production by MCs is important
at sites of infection (Goldszmid et al., 2012), the dependence on IRF8
for IL12 production in these cells should also be examined. Interest-
ingly, it has been proposed that IL-12 produced by peripheral DCs upon
infection can activate NK cells in the BM, that in response produce IFN-
γ locally (Askenase et al., 2015). One could envisage that such an al-
tered milieu in the BM could also induce epigenetic or even transcrip-
tional changes in the DC precursors biasing the generation toward
specific progeny on demand of the biological need. As recent reports in
both mice and humans have demonstrated that IRF8 expression as early
as the multipotent progenitor stage marked cells biased toward the
cDC1 lineage (Kurotaki et al., 2019; Lee et al., 2017), it would be in-
teresting to further investigate whether such priming of precursors
actually takes place under different settings.
As cDC1s typically do not develop in Irf8 and/or Batf3 deficient
mice, it is challenging to assess any additional functional role(s) for
these TFs in mature cDC1s. However, the requirement for BATF3 to
sustain IRF8 expression can be compensated for by Batf and Batf2
binding the same +32 kb Irf8 enhancer (Durai et al., 2019) in certain
conditions (Seillet et al., 2013; Tussiwand et al., 2012). The BATF3
dependency can also be artificially bypassed by crossing Batf3 knock-
out (Batf3−/−) mice with transgenic Irf8VENUS mice, which have an
increased copy number of endogenous Irf8 (Grajales-Reyes et al., 2015;
Theisen et al., 2019). By comparing Batf3+/+ Irf8VENUS+ and Batf3-/-
Irf8VENUS+ cDC1s, a role for BATF3 in cDC1-mediated tumor rejection
was uncovered, as BATF3 was found to specifically target a small set of
genes required by cDC1s to carry out this function (Theisen et al.,
2019). Additionally, administration of exogenous IL-12 in Batf3-/- mice
has also been shown to restore cDC1 development and the capacity to
cross-present antigen and mediate tumor rejection (Tussiwand et al.,
2012). This suggests that IL-12 provides additional signals, absent in
Batf3-/- Irf8VENUS+ mice, that can compensate for impaired tumor re-
jection (Theisen et al., 2019), although the transcriptional program that
dictates this compensation remains elusive.
3. Irf4
IRF4 is preferentially expressed by cDC2s (Guilliams et al., 2016)
and was originally proposed to be required for the specification of BM
progenitors toward splenic CD4+ cDCs or CD11bhi cDCs (Suzuki et al.,
2004; Tamura et al., 2005). Although full Irf4 deficient mice have a
reduced number of cDC2s in most tissues (Guilliams et al., 2016),
conditional deletion of the Irf4 gene in CD11c-expressing cells resulted
in an altered surface marker expression profile and functional deficits
(Bajaña et al., 2016, 2012; Krishnaswamy et al., 2017; Persson et al.,
2013; Schlitzer et al., 2013) of the cDC2 lineage but does not result in
the loss of the entire population. Thus while IRF4 controls some aspects
of cDC2 specification, it, unlike IRF8 in cDC1s, is not absolutely re-
quired for the presence of the entire cDC2 lineage. Phenotypically, loss
of Irf4 from the pre-cDC stage on in Irf4fl/fl mice driven by an ‘early-
acting’ Itgax-Cre (Caton et al., 2007) resulted in a reduction (although
not complete ablation) of specific cDC2 subtypes expressing CD24 in
the lung (Ainsua-Enrich et al., 2019; Bajaña et al., 2016; Schlitzer et al.,
2013) and the heart (Van der Borght et al., 2017), both CD24 and
CD103 in the intestine (Persson et al., 2013; Schlitzer et al., 2013),
CD103b (MGL2) in the skin (Gao et al., 2013) and CD4 in the spleen
(Bajaña et al., 2016; Suzuki et al., 2004; Tamura et al., 2005), although
whether this reduction is due to a lack of development or impaired
survival (see below) remains unclear. Functionally, IRF4 appears to
control CCR7-mediated migration of peripheral cDC2s to the draining
lymph nodes (LNs) (Ainsua-Enrich et al., 2019; Akbari et al., 2014;
Bajaña et al., 2016, 2012; Deckers et al., 2017; Van der Borght et al.,
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2018; Worbs et al., 2017) and favors a transcriptional module that
governs MHCII-dependent antigen presentation required for T cell
priming (Roquilly et al., 2017; Vander Lugt et al., 2014). IRF4 promotes
the expression of cathepsin S, H2-Oa and H2-DM, which are involved in
antigen loading into the peptide-binding pocket of MHC class II mole-
cules (Busch et al., 2000; Vander Lugt et al., 2014). In addition, IRF4
was found to negatively regulate March1, preventing MHCII surface
expression (Shin et al., 2006), and Cystatin C, which in turn inhibits the
activity of cathepsin S (Pierre and Mellman, 1998; Vander Lugt et al.,
2014). Therefore is tempting to speculate that a drop in IRF4 levels in
murine lung cDC1s and cDC2s induced upon resolution of pneumonia,
could be causally associated with the impaired innate and adaptive
immune responses against a secondary bacterial infection (Roquilly
et al., 2017). Moreover, in vitro cDC2-like cells and MCs induced by GM-
CSF and IL-4 required IRF4 to prime CD8+ T cells (Briseño et al., 2016),
opposed to in vivo cDC1s that rely on IRF8 and BATF3 for efficient cross-
presentation. Aside from roles in antigen presentation and migration,
IRF4 in cDC2s may also antagonize apoptosis (Persson et al., 2013;
Schlitzer et al., 2013; Sichien et al., 2017). Thus, it remains unclear
whether Irf4-deficient cDC2s fail to migrate because Ccr7 is directly
regulated by IRF4 and hence they die in the tissue unable to migrate or
if they die prematurely before they can acquire CCR7 expression. Evi-
dently, the induction of cytotoxic or T helper (Th) responses requires
efficient MHCI or MHCII presentation of transferred antigen in the LN.
Therefore the impaired survival and/or migration of specific subsets of
Irf4-deficient cDC2s could, at least partially, explain the deficient
priming of CD4 T cells to Th2 (Gao et al., 2013; Williams et al., 2013;
Zhou et al., 2014), Th17 (Persson et al., 2013; Schlitzer et al., 2013), T
regulatory (Treg) (Ainsua-Enrich et al., 2019; Vander Lugt et al., 2017)
or T follicular helper (Tfh) subtypes (Flores-Langarica et al., 2018a,
2018b; Krishnaswamy et al., 2017) that has been reported. Aside from
CD4 T cell priming, upon viral infection or specific PRR signals, cDC2s
can also function in CD8 T cell priming (unpublished and Ainsua-Enrich
et al., 2019; Ballesteros-Tato et al., 2010; Desch et al., 2014; Kim et al.,
2014; Shin et al., 2016), however, the underlying transcriptional pro-
gram that licenses cDC2s to initiate CD8 T cell responses remains to be
elucidated. Next to its role in survival and/or migration, some reports
indicate that IRF4 could also intrinsically control a functional gene
module in cDCs that drives Th specification under certain circum-
stances (Ainsua-Enrich et al., 2019; Akbari et al., 2014; Calabro et al.,
2016; Flores-Langarica et al., 2018a, 2018b; Krishnaswamy et al., 2017;
Laidlaw et al., 2015; Mayer et al., 2017; Moon et al., 2018; Negishi
et al., 2005; Persson et al., 2013; Schlitzer et al., 2013; Scott et al.,
2015; Vander Lugt et al., 2017; Williams et al., 2013).
4. Cooperation with Irf4 and Irf8
It was recently shown in humans that the discrimination between
pre-cDC1s and pre-cDC2s correlated with the ratio of IRF8 to IRF4
expression, indicating that the combinatorial dose of these TFs de-
termines fate decision (Ma et al., 2019; Villani et al., 2017). Further-
more, reciprocal expression of IRF4 and IRF8 in pre-cDC subsets might
directly prime distinctive molecular programming of the progeny,
thereby promoting the presentation of antigens via the MHCII or I
pathway, respectively (Vander Lugt et al., 2014). Since antagonism
between IRF4 and IRF8 has been demonstrated in activated B cell dif-
ferentiation (Xu et al., 2015), it is tempting to assume that competition
between both TFs would also contribute to the fate decision between
cDC1s and cDC2s. Further supporting this hypothesis, IRF4 is strongly
increased in uncommitted pre-cDCs and committed pre-cDC2s in the
absence of IRF8 which in turn might accelerate cDC2 development
(Sichien et al., 2016). In pDCs an increase in IRF4 expression com-
pensated for the loss of IRF8 as IRF4−/−IRF8−/− mice completely
lacked pDCs (Sichien et al., 2016). Next to the functional dichotomy of
IRF8 and IRF4 in cDCs, both TFs similarly correlated with the expres-
sion of genes encoding MHCII, CD80, CD86 and CCR7 in cDC1 and
cDC2 subsets, indicating that IRF8 and IRF4 also induce comparable
aspects of DC maturation (Schiavoni et al., 2004; Vander Lugt et al.,
2014). Even though cDC2s are not quantitatively affected by Irf8 or
Batf3 deficiency in steady state, expression of costimulatory molecules
and MHCII dependent antigen presentation was found to be impaired in
cDC2s derived from Irf8−/− mice (Aliberti et al., 2003; Mattei et al.,
2006). Therefore, further research is warranted to investigate whether
the loss of these subset-associated TFs could intrinsically affect the
functional maturation of cDC2s under certain conditions, and vice versa.
5. Klf4
Another TF associated with cDC2s is Kruppel-like factor 4 (KLF4).
Interestingly, KLF4 has been shown to be required for a subpopulation
of murine cDC2s. As such, Itgax-Cre Klf4fl/fl mice show a reduction of
cDC2s across lymphoid and non-lymphoid tissues, although the missing
cDC2 subsets differed in their surface expression pattern (Tussiwand
et al., 2015). For instance, loss of Klf4 selectively eliminated cDC2s
expressing CD24 and MGL2 (CD301b) in the lung, while compromising
the development of migratory CD11b−CD24− cDC2s in the skin.
Functionally, these KLF4-dependent cDC2s appear essential for
mounting Th2 responses to certain stimuli (Tussiwand et al., 2015),
consistent with reduced Th2 responses observed in reports using Itgax-
Cre Irf4fl/fl and Mgl2-DTR mice (Gao et al., 2013; Kumamoto et al.,
2013). Notably, KLF4 is not alone in regulating a subset of cDC2s (see
below).
6. Zeb1 and Zeb2
The ZEB proteins are a family TFs consisting of two members, ZEB1
and ZEB2 (Scott and Omilusik, 2019). While Zeb1 is expressed across
DC subsets in mice, Zeb2 expression is found in murine pDCs and cDC2s,
but absent in cDC1s (Miller et al., 2012; Scott and Omilusik, 2019).
Despite its wide expression across the cDC lineage, the role of ZEB1 in
cDCs and their progenitors remains largely unclear. In vitro Zeb1 knock
down in a murine tumor-derived DC cell line or FLT3L-induced BMDCs
reportedly results in impaired activation and cytokine secretion and a
Th2 biased response following DC:T cell coculture (Smita et al., 2018).
Thus it will be interesting to determine if this is also the case in vivo. The
other ZEB family member, ZEB2, was recently proposed to act as a
switch at the bifurcation of cDC1 and pDC fate specification (Bagadia
et al., 2019; Wu et al., 2016). However, it is currently questioned
whether pDCs and cDC1s actually share a common progenitor, as it was
proposed that pDCs may primarily develop from lymphoid progenitor
cells independently of the myeloid cDC lineage (Dress et al., 2019).
Nevertheless, it is clear that the presence of both cDC1s and pDCs rely
on the mutually exclusive repression of either ZEB2 or ID2 in addition
to their use of distinct Irf8 enhancers (see above). Repression of ZEB2
by NFIL3 leading to increased ID2 expression is essential for cDC1
specification at the CDP stage (Bagadia et al., 2019; Wu et al., 2016),
while in pDCs, ZEB2 is required for their development and maintenance
(Scott et al., 2016; Wu et al., 2016), presumably through inhibition of
ID2 which in turn antagonizes Tcf4 expression (Ghosh et al., 2010).
Zeb2 is also consistently expressed throughout the development and
maturation of the cDC2 lineage (Schlitzer et al., 2015). Although loss of
Zeb2 only slightly affected cDC2 numbers in a cell-intrinsic manner, this
effect varied between cDC2 subsets in different tissues (Scott et al.,
2016; Wu et al., 2016), while Zeb2fl/fl mice crossed with a “late-acting”
Itgax-Cre did not have a defect in cDC2 numbers. Taken together, these
data suggest that ZEB2 may act early in cDC2 development, in a specific
subset manner (Scott et al., 2016). In the future, the use of cDC subset-
specific Zeb2 deletion may help to unravel the cell-intrinsic effects of
Zeb2 deficiency on DC function.
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7. Notch
Apart from cell-intrinsic effects of certain TFs, tissue-specific sig-
nals, such as NOTCH ligands or lymphotoxin β (LTβ), can inform DCs of
their surroundings and thereby guide their differentiation and function
(Cheng et al., 2007; Fasnacht et al., 2014). NOTCH receptors transmit
signals from membrane-bound ligands of the Delta-like (DL) and Jagged
(Jag) families through the common TF RBPjk. It has been shown that
NOTCH2-RBPjk signaling is involved in the terminal differentiation of a
cDC2 subset expressing ESAM localized in the marginal zone bridging
channels of the spleen and CD103 in the small intestine (Caton et al.,
2007; Lewis et al., 2011; Satpathy et al., 2013) without actually af-
fecting the development of cDC precursors. Mice devoid of TF RUNX3
displayed a similar loss of ESAM+ cDC2s, potentially through direct
interactions with RBPjk (Dicken et al., 2013). Functionally, NOTCH2-
signaling in cDCs is required for IL-23 production in the innate defense
against C. rodentium (Satpathy et al., 2013). Moreover a reduced frac-
tion of intestinal Th17 cells, previously associated with the lack of
CD103+ intestinal cDC2s (Lohoff et al., 2002; Persson et al., 2013;
Schlitzer et al., 2013), was found in Itgax-Cre Notch2fl/fl mice in steady
state (Lewis et al., 2011), although others have shown that NOTCH2
signaling was dispensable to mount Th17 responses to certain bacteria
(Linehan et al., 2015; Panea et al., 2015). Since CD103− cDC2s are not
quantitively affected upon loss of Notch2, it is possible that the
CCR2+CD103− cDC2 subset in the intestine compensates for Th17
induction (Scott et al., 2015), although the Notch independency of this
subset remains to be shown. Moreover, NOTCH2-signaling appeared to
be dispensable for mounting Th2 responses against S. mansoni
(Tussiwand et al., 2015) or differentiation of peripheral Tregs (Nutsch
et al., 2016). A recent study implied a role for Notch2-dependent cDC2s
in mediating Tfh differentiation and germinal center (GC) responses in
the spleen, but not in Peyer Patches (Briseño et al., 2018). Next to the
quantitative defect of splenic cDCs (i.e. ESAM+ subsets), in Itgax-Cre
Notch2fl/flmice (Satpathy et al., 2013) this effect was further ascribed to
qualitative changes in gene expression of the Notch2-deficient cDC2s
(Briseño et al., 2018). However, the functional module targeted by
NOTCH2 in cDC2s that favors Tfh priming (Briseño et al., 2018) or
determines the correct anatomical localization in the spleen (Lu et al.,
2017; Satpathy et al., 2013) remains elusive. One concern regarding
this latter study (Briseño et al., 2018) is that the Itgax-Cre system re-
portedly causes leakiness in B and T cells (Krishnaswamy et al., 2017;
Schlitzer et al., 2013) thus Tfh differentiation may be impaired due to
targeting T cell-intrinsic NOTCH2-signaling (Auderset et al., 2013;
Dell’aringa and Lee Reinhardt, 2018). Therefore, future studies will
have to examine the DC-intrinsic role of Notch2 in these observations by
using more specific conditional deletion models, chimeras and/or ex
vivo assays with purified subsets. Moreover, it remains to be shown
whether cDC2s are involved in a Notch2-dependent way in Tfh differ-
entiation in humans as observed in mice (Durand et al., 2019). Next to
NOTCH instruction, splenic ESAM+ and intestinal CD103+ cDC2s also
rely on downstream LTβR signaling through ligands provided by the
local environment (Kabashima et al., 2005; Satpathy et al., 2013; Wang
et al., 2005), but how both pathways interact remains to be elucidated.
Interestingly, in order to correctly localize in the marginal zone brid-
ging channels NOTCH2- and LTβR-dependent cDC2s require expression
of chemokine receptor Epstein-Barr virus-induced G-protein coupled
receptor 2 (EBI2, encoded by Gpr183) (Gatto et al., 2013; Yi and Cyster,
2013). Since the loss of splenic CD4+ cDC2s in Gpr183-deficient mice
could be rescued by LTβR-agonism (Yi and Cyster, 2013), it is tempting
to speculate that EBI2 drives the positioning of cDC2s into a niche that
provides NOTCH and LTβR ligands. Therefore it will be interesting to
assess the role of NOTCHsignaling in the anatomical positioning of DCs
in future research.
Next to cDC2s, Notch2-deficiency also affected the terminal ma-
turation of cDC1s in the spleen (Lewis et al., 2011; Satpathy et al.,
2013). Given the key role of NOTCH signaling in cDC progenitors for
terminal differentiation, an alternative in vitro ‘cDC1′ culture system for
both mouse and human was recently developed that uses the FLT3L
system (Naik et al., 2005) in combination with a stromal cell line (OP9)
expressing DLL1 (Kirkling et al., 2018). While pDC development was
largely abolished, these in vitro generated cDC1s more closely aligned
with their primary counterparts (Kirkling et al., 2018), further em-
phasizing the key role of NOTCH signaling in terminal cDC differ-
entiation. Another in vitro differentiation method similarly showed that
NOTCH signaling in a GM-CSF system promoted cDC1 generation from
human CD34+ precursors (Balan et al., 2018).
8. Tbet
Although typically thought of as a TF associated with T helper cell
and innate lymphoid cell (ILC) subsets, recently, Tbet expression, re-
ported through the use of Tbx21RFP−Cre mice, has also been suggested
to delineate two subsets of cDC2s (Brown et al., 2019), with those
cDC2s expressing Tbet being termed cDC2As, while cDC2Bs lacked
expression of this TF (Brown et al., 2019). Notably, this is not the first
time Tbet expression has been reported in cDC2s (Lugo-Villarino et al.,
2003; Wang et al., 2006). Functionally, these two populations were also
suggested to be distinct, with cDC2As being more anti-inflammatory
than their cDC2B counterparts (Brown et al., 2019). However, this
appears somewhat at odds with the original studies suggesting that lack
of Tbet expression in cDCs protected mice from collagen antibody in-
duced arthritis (Wang et al., 2006) and that Tbet expression was re-
quired for IFN-γ production by cDCs (Lugo-Villarino et al., 2003). While
IFN-γ production from cDC2As and cDC2Bs was not assessed in the
recent study, preventing the direct comparison, the authors found that
cDC2Bs were better at inducing IFN-γ+ Th1 cells in non-polarizing
conditions than cDC2As (although levels of IFN-γ measured were re-
latively low) (Brown et al., 2019), which was previously attributed to
the Tbet-dependent DCs (Lugo-Villarino et al., 2003; Wang et al., 2006).
However, Brown and colleagues also observed that IFN-γ promoted Tbet
expression in cDC2s (Brown et al., 2019). As the original studies used
total CD11c+MHCII+ cells from WT or Tbet KO mice and did not dis-
criminate Tbet+ from Tbet- cDCs, one possible hypothesis to explain
this discrepancy, could be that Tbet-expressing cDC2As may promote
IFN-γ production from cDC2Bs which in turn promote cDC2As creating
a loop to ensure sufficient IFN-γ production from cDC2s when required.
However, this remains to be formally investigated.
Although the proportions of cDC2As and cDC2Bs differed, both
subsets were identified across several murine tissues. Focusing on those
found in the murine spleen, despite an enrichment for binding sites of
Rbpj and Runx in cDC2As suggesting a role for NOTCH signaling, the
authors concluded that Tbet expression did not perfectly correlate with
ESAM expression, although further investigation may be warranted
based on mRNA expression profiles (Brown et al., 2019). Additionally,
while CLEC10A and CLEC12A could be used to further distinguish
cDC2Bs into different fractions, no perfect markers were reported to
accurately distinguish between cDC2As and cDC2Bs (Brown et al.,
2019). The presence of further subsets of cDC2Bs, also suggests there
could be further heterogeneity within the population not accounted for
by Tbet expression. For example, despite being expressed across
cDC2As and cDC2Bs (Brown et al., 2019), loss of KLF4 selectively af-
fects CLEC12A+ cDC2Bs in the spleen (Tussiwand et al., 2015 and re-
viewed in detail in Murphy et al., 2016). In addition, it remains to be
seen how traditional markers used to delineate cDC2 subsets in other
tissues, for example CD103 in the intestine, fair when it comes to di-
viding the Tbet+ and Tbet− fractions.
Despite the potential for further heterogeneity within the cDC2s,
intriguingly, ATAC-Seq analysis revealed that cDC2As were enriched
for binding sites for ID2 and NFIL3 when compared with cDC2Bs
(Brown et al., 2019), thus given the relationship identified by the lab of
Ken Murphy between these TFs and ZEB2 (Bagadia et al., 2019) it is
tempting to speculate that Tbet expression could delineate the subset of
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cDC2s existing independently of ZEB2 expression (Scott et al., 2016;
Wu et al., 2016), as NFIL3 would inhibit ZEebBEBEB2 expression which
would in turn enable ID2 to be expressed. Potentially fitting with this
hypothesis, when the authors compared human and murine splenic
cDC2s to find counterparts, ZEB2 was one of the defining TFs found to
overlap between human and murine cDC2Bs (Brown et al., 2019).
Additionally Zeb2 expression level does seem to distinguish between
two cDC2s subsets in the murine spleen (unpublished data) however
both subsets express Zeb2 compared with cDC1s (Scott and Omilusik,
2019 and unpublished data), perhaps this could be explained by a lower
expression of NFIL3 in cDC2s than cDC1s. Indeed, this requires a fur-
ther, more in-depth examination.
As mentioned above cDC2A and cDC2B counterparts were also
identified in human splenic tissue, expressing CLEC4A and CLEC10A
respectively, where they appeared to have similar functional properties
to those in the mouse (Brown et al., 2019). Notably, CLE-
C10A−CLEC4A+ cDC2As were only found in the spleen and not in
human PBMCs highlighting the need to also examine human tissue
(Brown et al., 2019). While Tbet+ cDC2 equivalents were not found in
human blood in this study, many recent studies have also highlighted a
significant amount of heterogeneity in the cDC2 populations present
within PBMCs (Dutertre et al., 2019; Günther et al., 2019; See et al.,
2017; Villani et al., 2017). This suggests that, similar to the mouse, Tbet
expression alone is likely not sufficient to explain all cDC2 hetero-
geneity in humans. The most recent study, upon bringing together all
this data, proposed that there are two main cDC2 subsets present within
the PBMC population based on expression of CD5 and CD163 which
were termed cDC2 (CD5-) and cDC3 (CD5+CD163+). Here, the cDC3
population were identified to be the most inflammatory and fitting with
this were also increased in proportion in SLE patients (Dutertre et al.,
2019). While NOTCH2 was more highly expressed than KLF4 in the
cDC3s (Dutertre et al., 2019), which TFs may specify these populations
remains an open question for the future. However, with their shared
expression of NOTCH, the link between the cDC3s and cDC2As also
requires closer attention.
9. Conclusion
In the last decade significant progress has been made in our un-
derstanding of DC development and the different mature cDC popula-
tions across species and tissues (Fig. 1). Although cDCs are commonly
divided in two main lineages (cDC1s and cDC2s) based on ontogeny
(Guilliams et al., 2014) and relating to function and phenotype, it has
become apparent that the cDC2s, still represent a heterogeneous po-
pulation. This heterogeneity is furthermore reflected by the differential
reliance on certain TFs, depending on the tissue and/or event that
Fig. 1. Recent advances in cDC fate specification by Transcription
Factors.
Summary figure detailing recent advances in our understanding of
transcriptional control of DC fate, highlighting remaining un-
knowns and main questions for the future. cDC1s develop from
CDPs through pre-cDC1 intermediates. In mice, progression to
cDC1 is achieved through increasing expression of IRF8 and
switching from the +41 kb enhancer to the +32 kb enhancer at
the pre-cDC stage. cDC1s express IRF8, BATF3, ID2, NFIL3 (red
arrows) and absolutely require IRF8 (maintained through BATF3
and IRF8 autoactivation) for their development and maintenance.
Expression of NFIL3, inhibits ZEB2 expression which in turn en-
ables ID2 expression, normally repressed by ZEB2. Like cDC1s,
cDC2s develop from CDPs but via a pre-cDC2 intermediate. There
is still much to learn regarding cDC2s. Typically IRF4 is thought of
as the main cDC2 TF in mice, however, it is not required for the
development of all subsets, but may instead be important for
survival and/or migration of specific subsets. In recent years,
considerable heterogeneity has been demonstrated within the
cDC2 population including the recent description of Tbet+ and
Tbet− cDC2s termed cDC2As and cDC2Bs respectively identified
in mouse and human spleen. To date no distinct precursors for
these subsets have been identified. In mice, cDC2As appear to also
express and require NOTCH signaling being enriched for Rbpj and
Runx binding sites. Whether Tbet is absolutely required for
cDC2As remains to be studied. Some evidence suggests murine
cDC2Bs (or a subset thereof), may require ZEB2 for their devel-
opment but this remains to be directly investigated. Clec12A+
cDC2Bs, one subset of cDC2Bs, have been shown to require KLF4
in mice. Requirements for the other subsets remain to be studied.
In human PBMCs, a pro-inflammatory cDC3 population has also
recently been described, the TFs mediating this population and the
precise progenitor remain to be identified however, they were
shown to express higher NOTCH2 than KLF4. Thus the relation-
ship of these cDC3s to cDC2As requires further investigation. Key
questions for the future, especially related to heterogeneity within
the cDC2 lineage, including understanding the role of the tissue
microenvironment in cDC2 biology. How many distinct popula-
tions of cDC2s are there? Are there different subsets based on
tissue? Do distinct TFs play a role in each tissue to generate the
final cDC2 phenotype? Are cDC2 subsets arising from distinct
developmental pathways or do they represent alternative activa-
tion states? Understanding this, will be a main goal in the coming
years.
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disrupts homeostasis. While a set of TFs appear to be required for the
development of the entire cDC1 (e.g. Irf8 Sichien et al., 2016) or pDC
(e.g. Tcf4, Zeb2, Cisse et al., 2008; Scott et al., 2016; Wu et al., 2016)
lineages, no single transcriptional regulator has yet been identified that
is essential for cDC2 development or maintenance. However, this is
perhaps not surprising given the level of heterogeneity observed within
this populations. Future research will need to further consider and
define the contextual signals that influence the transcriptional program
of different subsets of cDC2s in any specific location as perhaps similar
to what is seen for macrophages (Lavin et al., 2014), local environ-
mental features may be key in understanding these populations.
Moreover, whether the heterogeneity in transcriptional program within
the cDC subsets, and in particular cDC2s, relates to specific differ-
entiation programs induced in the primed T cells will have to be de-
termined by future studies. A better understanding of the transcrip-
tional and functional adaptation cDC subtypes will ultimately provide a
basis for better therapeutic strategies in humans.
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